Product Image
Please see full prescribing and safety information, including boxed warning, for DESMOPRESSIN single-dose vials and multi-dose vials.

Available in:

  • 4 mcg per 1 mL single-dose vials*
  • 40 mcg per 10 mL multi-dose vials


  • AP Rated
  • Not made with natural rubber latex
  • *Preservative-free

DESMOPRESSIN Acetate Injection, USP*

Therapeutic Category: Hormone

PreventIV Measures® Features:

  • Easy-to-read drug name and dosage strength to aid in identifying the right product
  • Bar codes included on the vial and carton for ease of scanning
  • Unique label design to help products stand out on the shelf
  • Enhanced packaging and labeling designed to promote safety and help reduce the risk of medication errors
Description Strength Fill
Concentration Container
Closure Unit
of Sale
460-01 Glass Vial 4 mcg 1 mL 4 mcg per mL 2 mL 13 mm 10
461-10 Glass Vial 40 mcg 10 mL 4 mcg per mL 10 mL 20 mm 1


Desmopressin acetate can cause hyponatremia. Severe hyponatremia can be life-threatening, leading to seizures, coma, respiratory arrest, or death [see Warnings and Precautions (5.1)].

Desmopressin acetate is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids [see Contraindications (4) and Warnings and Precautions (5.1)].

Ensure the serum sodium concentration is normal before starting or resuming desmopressin acetate. Measure serum sodium within 7 days and approximately 1 month after initiating therapy, and periodically during treatment. More frequently monitor serum sodium in patients 65 years of age and older and in patients at increased risk of hyponatremia [see Dosage and Administration (2.1) and Warnings and Precautions (5.1)].

If hyponatremia occurs, desmopressin acetate may need to be temporarily or permanently discontinued [see Warnings and Precautions (5.1)].